| Database ID | Agent | Target | Cancer Type | Detail |
| DB00106 | everolimus | Serine/threonineprotein kinase mTOR | liver cancer | view |
| DB00107 | ramucirumab | Vascular endothelial growth factor receptor 2 | liver cancer | view |
| DB00108 | tivantinib | Protooncogene cMet | liver cancer | view |
| DB00109 | ramucirumab | Vascular endothelial growth factor receptor 2 | liver cancer | view |
| DB00110 | regorafenib | Protooncogene tyrosineprotein kinase receptor ret
Mast/stem cell growth factor receptor
Vascular endothelial growth factor receptor 2
Vascular endothelial growth factor receptor 3 | liver cancer | view |
| DB00111 | bevacizumab, temsirolimus | NA | liver cancer | view |
| DB00112 | bevacizumab | Vascular endothelial growth factor
Epidermal growth factor receptor | liver cancer | view |
| DB00113 | bevacizumab | Vascular endothelial growth factor | liver cancer | view |
| DB00114 | bevacizumab | Vascular endothelial growth factor | liver cancer | view |
| DB00115 | lapatinib | Epidermal growth factor receptor
Receptor proteintyrosine kinase erbB2 | liver cancer | view |
| DB00116 | lapatinib | Epidermal growth factor receptor
Receptor proteintyrosine kinase erbB2 | biliary tract, gallbladder cancer and liver cancer | view |
| DB00117 | erlotinib | Epidermal growth factor receptor | liver cancer | view |
| DB00118 | erlotinib | Epidermal growth factor receptor | biliary tract and gallbladder cancer | view |
| DB00119 | erlotinib | Epidermal growth factor receptor | head and neck cancer | view |
| DB00120 | cediranib | Vascular endothelial growth factor receptor 2 | liver cancer | view |